Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EBOS Group Limited ( (AU:EBO) ) has issued an update.
EBOS Group Limited has released its interim report for the six months ended 31 December 2025, providing shareholders with condensed consolidated financial statements and accompanying notes. The report includes an independent auditor’s review, income statement, balance sheet, cash flow statement and statement of changes in equity, offering a snapshot of the company’s financial performance and position at the halfway point of its 2026 financial year.
While the document outline does not disclose specific figures or performance metrics, the interim report’s publication ensures continued transparency and regulatory compliance for investors and other stakeholders. It also signals that EBOS is maintaining regular financial reporting practices, giving the market updated visibility on its operations and financial health during the period.
The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a diversified healthcare and pharmaceutical company operating across Australasia, supplying medicines, medical devices and related services to pharmacies, hospitals and other healthcare providers. The group plays a key role in regional healthcare distribution and services, supporting both community and institutional health markets.
Average Trading Volume: 136,505
Technical Sentiment Signal: Sell
Current Market Cap: A$4.29B
Find detailed analytics on EBO stock on TipRanks’ Stock Analysis page.